The gut microbiota and diabetic cardiomyopathy in humans

Area of Science:

• Cardiology
• Endocrinology
• Microbiology

Background:

• Type 2 diabetes (DT2) significantly elevates cardiovascular event risk, including cardiac insufficiency.
• Diabetic cardiomyopathy, driven by hyperglycemia and lipotoxicity, is a key cause of cardiac insufficiency in DT2 patients.
• Cardiac dysfunction in DT2 involves cardiomyocyte hypertrophy, apoptosis, fibrosis, and reduced contractility.

Purpose of the Study:

• To explore the link between diabetic cardiomyopathy and intestinal microbiota modifications.
• To investigate the role of bacterial metabolites in cardiac dysfunction.
• To establish the 'microbiota-myocardium' axis and its therapeutic potential.

Main Methods:

• Review of existing studies on diabetic cardiomyopathy and gut microbiota.
• Analysis of bacterial metabolite synthesis and host diffusion.
• Pathophysiological investigation of the microbiota-myocardium interaction.

Main Results:

• Diabetic cardiomyopathy is associated with altered intestinal microbiota composition.
• Specific bacterial metabolites may exert direct detrimental effects on cardiac contractility.
• Evidence supports a 'microbiota-myocardium' axis influencing cardiac health in DT2.

Conclusions:

• Intestinal dysbiosis is implicated in the pathogenesis of diabetic cardiomyopathy.
• Targeting gut microbiota dysbiosis offers a novel therapeutic avenue for cardiac insufficiency in DT2.
• Correction of intestinal dysbiosis may improve outcomes in high-risk DT2 patients with cardiac insufficiency.